A citation-based method for searching scientific literature

Karan Seegobin, Umair Majeed, Nathaniel Wiest, Rami Manochakian, Yanyan Lou, Yujie Zhao. Front Oncol 2021
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.
Kenneth S Thress, Cloud P Paweletz, Enriqueta Felip, Byoung Chul Cho, Daniel Stetson, Brian Dougherty, Zhongwu Lai, Aleksandra Markovets, Ana Vivancos, Yanan Kuang,[...]. Nat Med 2015
945
100

KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC.
Marika Cinausero, Noemi Laprovitera, Giovanna De Maglio, Lorenzo Gerratana, Mattia Riefolo, Marianna Macerelli, Michelangelo Fiorentino, Elisa Porcellini, Vanessa Buoro, Francesco Gelsomino,[...]. Ther Adv Med Oncol 2019
10
100

Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.
Lecia V Sequist, Joachim von Pawel, Edward G Garmey, Wallace L Akerley, Wolfram Brugger, Dora Ferrari, Yinpu Chen, Daniel B Costa, David E Gerber, Sergey Orlov,[...]. J Clin Oncol 2011
332
100

Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer.
Eri Sugiyama, Yosuke Togashi, Yoshiko Takeuchi, Sayoko Shinya, Yasuko Tada, Keisuke Kataoka, Kenta Tane, Eiichi Sato, Genichiro Ishii, Koichi Goto,[...]. Sci Immunol 2020
49
100

Characterization of distinct types of KRAS mutation and its impact on first-line platinum-based chemotherapy in Chinese patients with advanced non-small cell lung cancer.
Yijun Jia, Tao Jiang, Xuefei Li, Chao Zhao, Limin Zhang, Sha Zhao, Xiaozhen Liu, Meng Qiao, Jiawei Luo, Jinpeng Shi,[...]. Oncol Lett 2017
20
100

Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.
S Li, L Li, Y Zhu, C Huang, Y Qin, H Liu, L Ren-Heidenreich, B Shi, H Ren, X Chu,[...]. Br J Cancer 2014
138
100

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
100

Emerging biomarkers for immune checkpoint inhibition in lung cancer.
George Cyriac, Leena Gandhi. Semin Cancer Biol 2018
55
100

EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research.
Rui-Fang Dong, Miao-Lin Zhu, Ming-Ming Liu, Yi-Ting Xu, Liu-Liu Yuan, Jing Bian, Yuan-Zheng Xia, Ling-Yi Kong. Pharmacol Res 2021
13
100


KRAS mutation: should we test for it, and does it matter?
Patrick J Roberts, Thomas E Stinchcombe. J Clin Oncol 2013
178
100

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
Martin Reck, Tony S K Mok, Makoto Nishio, Robert M Jotte, Federico Cappuzzo, Francisco Orlandi, Daniil Stroyakovskiy, Naoyuki Nogami, Delvys Rodríguez-Abreu, Denis Moro-Sibilot,[...]. Lancet Respir Med 2019
381
100

Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC).
J Nicholas Bodor, Yanis Boumber, Hossein Borghaei. Cancer 2020
81
100


Distribution of PD-L1 expression and its relationship with clinicopathological variables: an audit from 1071 cases of surgically resected non-small cell lung cancer.
Qian Chen, Yi-Yun Fu, Qiao-Ni Yue, Qian Wu, Yuan Tang, Wei-Ya Wang, Yong-Sheng Wang, Li-Li Jiang. Int J Clin Exp Pathol 2019
11
100

The association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials.
Yangyang Xu, Bing Wan, Xi Chen, Ping Zhan, Yuan Zhao, Tianli Zhang, Hongbing Liu, Muhammad Zubair Afzal, Said Dermime, Steven N Hochwald,[...]. Transl Lung Cancer Res 2019
38
100

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
Luis Paz-Ares, Tudor-Eliade Ciuleanu, Manuel Cobo, Michael Schenker, Bogdan Zurawski, Juliana Menezes, Eduardo Richardet, Jaafar Bennouna, Enriqueta Felip, Oscar Juan-Vidal,[...]. Lancet Oncol 2021
197
100

Targeted next-generation sequencing for cancer-associated gene mutation and copy number detection in 206 patients with non-small-cell lung cancer.
Songbai Zheng, Xiaodan Wang, Ying Fu, Beibei Li, Jianhua Xu, Haifang Wang, Zhen Huang, Hui Xu, Yurong Qiu, Yaozhou Shi,[...]. Bioengineered 2021
4
100

Adjuvant EGFR-TKIs for Patients With Resected EGFR-Mutant Non-Small Cell Lung Cancer: A Meta-Analysis of 1,283 Patients.
Rui-Lian Chen, Ling-Ling Sun, Yang Cao, Han-Rui Chen, Jing-Xu Zhou, Chu-Ying Gu, Ying Zhang, Si-Yu Wang, Wei Hou, Li-Zhu Lin. Front Oncol 2021
4
100

Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Runsen Jin, Chengming Liu, Sufei Zheng, Xinfeng Wang, Xiaoli Feng, Hecheng Li, Nan Sun, Jie He. Cancer Biol Med 2020
10
100

Inhibition of epidermal growth factor receptor improves antitumor efficacy of vemurafenib in BRAF-mutant human melanoma in preclinical model.
István Kenessey, Zsófia Kramer, Lilla István, Mihály T Cserepes, Tamás Garay, Balázs Hegedűs, Judit Dobos, József Tímár, József Tóvári. Melanoma Res 2018
12
100

A combination of PD‑1/PD‑L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review).
Xianbin Kong, Peng Lu, Chuanxin Liu, Yuzhu Guo, Yuying Yang, Yingying Peng, Fangyuan Wang, Zhichao Bo, Xiaoxin Dou, Haoyang Shi,[...]. Mol Med Rep 2021
5
100

Multiplicity of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitors.
Lucie Benesova, Marek Minarik, Dana Jancarikova, Barbora Belsanova, Milos Pesek. Anticancer Res 2010
40
100

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
J Mazieres, A Drilon, A Lusque, L Mhanna, A B Cortot, L Mezquita, A A Thai, C Mascaux, S Couraud, R Veillon,[...]. Ann Oncol 2019
345
100

Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA.
Marzia Del Re, Marcello Tiseo, Paola Bordi, Armida D'Incecco, Andrea Camerini, Iacopo Petrini, Maurizio Lucchesi, Alessandro Inno, Daniele Spada, Enrico Vasile,[...]. Oncotarget 2017
63
100

Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
Xibin Zhuang, Chao Zhao, Jiayu Li, Chunxia Su, Xiaoxia Chen, Shengxiang Ren, Xuefei Li, Caicun Zhou. Cancer Med 2019
28
100

A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).
Yuankai Shi, Joseph Siu-Kie Au, Sumitra Thongprasert, Sankar Srinivasan, Chun-Ming Tsai, Mai Trong Khoa, Karin Heeroma, Yohji Itoh, Gerardo Cornelio, Pan-Chyr Yang. J Thorac Oncol 2014
737
100

A gene expression-based immune signature for lung adenocarcinoma prognosis.
Lijuan Wang, Xizhi Luo, Chao Cheng, Christopher I Amos, Guoshuai Cai, Feifei Xiao. Cancer Immunol Immunother 2020
9
100

Transcriptional activation of cyclin D1 via HER2/HER3 contributes to EGFR-TKI resistance in lung cancer.
Bin Liu, Deng Chen, Shipeng Chen, Ali Saber, Hidde Haisma. Biochem Pharmacol 2020
6
100

The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients.
Anna Maria Rachiglio, Francesca Fenizia, Maria Carmela Piccirillo, Domenico Galetta, Lucio Crinò, Bruno Vincenzi, Emiddio Barletta, Carmine Pinto, Francesco Ferraù, Matilde Lambiase,[...]. Cancers (Basel) 2019
24
100

Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases.
Taebum Lee, Boram Lee, Yoon-La Choi, Joungho Han, Myung-Ju Ahn, Sang-Won Um. J Pathol Transl Med 2016
57
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.